New weight-loss treatment becomes first FDA-approved drug for sleep apnea

The FDA approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, the first drug to directly treat the disorder. The approval is for moderate to severe obstructive sleep apnea in adults with obesity, potentially expanding the market and strengthening Lilly’s case with insurers. Zepbound, a GLP-1 agonist, also reduces food cravings and slows stomach emptying, with trial data showing it eased breathing difficulties and lowered sleep apnea biomarkers.